Skip to content

The effect of sildenafil and metformin on sexual function

Evaluation of the effect of sildenafil along with metformin on the sexual function of patients with polycystic ovary syndrome treated with metformin.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160524028038N16
Enrollment
108
Registered
2023-02-08
Start date
2023-02-19
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Sildenafil (sildenafil citrate (Vizarcin) 25 mg daily) + metformin tablets (500 mg three times a day orally). Intervention 2: Control group: metformin tablets (500

Sponsors

Bandare-abbas University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 45 years Body mass index 19-25 Confirmation of polycystic ovary syndrome based on the Rotterdam criteria

Exclusion criteria

Exclusion criteria: Patients who do not want to cooperate. Sildenafil sensitivity and intolerance to side effects (hot flashes, vision disorders, severe drop in blood pressure and hearing disorders) pregnancy Taking ocp or ovulation stimulation drugs Existence of severe mental conditions since 6 months before the research, which has an adverse effect on the patient's quality of life Suffering from a severe degree of depression and anxiety according to the depression and anxiety questionnaire based on the Beck depression and anxiety questionnaire Current use of psychiatric medications Language or cognitive problems preventing the patient from completing the questionnaire smoking Current use of drugs affecting sexual performance Previous diagnosis of an organic cause for sexual dysfunction by an experienced physician Taking vasodilator drugs and drugs that interact with metformin, silde.

Design outcomes

Primary

MeasureTime frame
Sexual function. Timepoint: Before the intervention and three after the intervention. Method of measurement: sexual function questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Azizi

Bandare-abbas University of Medical Sciences

Maryamazizikut86@gmail.com+98 76 3333 0755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026